Biodexa Pharmaceuticals (BDRX) AI Stock Analysis

• Market Cap: $942.72K
• Dividend Yield: N/A
• Average Volume (3M): 833.21K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.63
• Revenue Growth: -83.72%
• EPS Growth: 99.56%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -17.42
• Shares Outstanding: 2,561,741
• 10 Day Avg. Volume: 54,602
• 30 Day Avg. Volume: 833,214
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $18.00
• Price Target Upside: 1176.60% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

Biodexa Pharmaceuticals has a low overall stock score of 45, driven by significant financial challenges, bearish technical indicators, and a poor valuation. The lack of positive earnings guidance further adds to the uncertainty. The company must improve financial performance and operational efficiency to enhance investor confidence.

Biodexa Pharmaceuticals Business Overview & Revenue Model

Company Description

Biodexa Pharmaceuticals (BDRX) is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Operating primarily in the pharmaceutical sector, the company specializes in the research and development of drug delivery systems and proprietary drug formulations designed to enhance patient outcomes. Its core products include advanced pharmaceutical compounds and delivery technologies that address unmet medical needs in various therapeutic areas.

How the Company Makes Money

Biodexa Pharmaceuticals makes money through the development and commercialization of its pharmaceutical products and drug delivery technologies. The company's revenue model is primarily based on sales of its proprietary drug formulations and delivery systems to healthcare providers, pharmaceutical companies, and distributors. Additionally, Biodexa may engage in strategic partnerships or licensing agreements with other pharmaceutical companies to further develop and market its technologies, which can provide additional revenue streams through milestone payments, royalties, or co-development deals. Key factors contributing to its earnings include successful clinical trials, regulatory approvals, and the ability to effectively market its products to target demographics.

Biodexa Pharmaceuticals Financial Statement Overview

Summary

Biodexa Pharmaceuticals demonstrates weak financial performance with declining revenues, negative profitability margins, and persistent cash flow issues. Despite a favorable debt-to-equity ratio, the overall financial health is compromised by ongoing losses and inefficiencies in generating profits.

Income Statement

Biodexa Pharmaceuticals shows a decreasing revenue trend over the years with a significant decline from $674,000 in 2019 to $381,000 in 2023. The gross profit margin is negative, indicating cost of goods sold surpasses revenue. Net profit margin is also negative, representing ongoing unprofitability. Despite some improvement in EBITDA margin, overall financial health remains weak due to persistent losses.

Balance Sheet

The debt-to-equity ratio is favorable, with relatively low leverage indicating the company relies more on equity than debt for financing. The equity ratio is stable, reflecting moderate financial stability. However, consistent negative net income impacts the return on equity, suggesting inefficiencies in generating profits from shareholders' equity.

Cash Flow

Operating cash flow remains negative, signaling challenges in generating cash from operations. Free cash flow shows a slight improvement but remains negative, indicating ongoing cash burn. The operating cash flow to net income ratio suggests that cash generation issues are consistent with net losses. Financing activities are primarily funding operations, as seen from significant cash inflows.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
381.00K	699.00K	578.00K	343.00K	674.00K
	Gross Profit
-3.69M	-4.41M	-4.08M	-5.72M	-7.17M
	EBIT
-8.01M	-8.93M	-7.00M	-10.67M	-11.32M
	EBITDA
-7.16M	-7.39M	-5.66M	-22.22M	-9.54M
	Net Income Common Stockholders
-7.08M	-7.66M	-5.46M	-22.19M	-9.14M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
5.97M	2.84M	10.06M	7.55M	10.93M
	Total Assets
10.54M	5.53M	12.91M	9.82M	30.89M
	Total Debt
464.00K	624.00K	766.00K	260.00K	6.08M
	Net Debt
-5.51M	-2.21M	-9.29M	-7.29M	-4.85M
	Total Liabilities
5.86M	2.36M	2.46M	3.10M	11.34M
	Stockholders Equity
4.68M	3.16M	10.45M	6.72M	19.56M
Cash Flow		Free Cash Flow
-7.09M	-7.11M	-6.33M	-9.51M	-6.81M
	Operating Cash Flow
-6.83M	-7.05M	-6.01M	-9.30M	-6.49M
	Investing Cash Flow
-265.00K	-220.00K	-278.00K	2.57M	-3.81M
	Financing Cash Flow
10.23M	47.00K	8.80M	3.08M	18.73M

Biodexa Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.41
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BDRX, the sentiment is Negative. The current price of 1.41 is below the 20-day moving average (MA) of 1.46, below the 50-day MA of 1.79, and below the 200-day MA of 6.04, indicating a bearish trend. The MACD of -0.12 indicates Negative momentum. The RSI at 41.59 is Neutral, neither overbought nor oversold. The STOCH value of 41.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BDRX.

Biodexa Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FRX	58 Neutral	$235.96M	―	21.91%	―	125.38%	99.20%
Sector *	52 Neutral	$5.15B	3.56	-42.52%	2.83%	14.56%	-0.53%
MRNS	48 Neutral	$30.37M	―	210.50%	―	1.63%	6.97%
BDRX	45 Neutral	$942.72K	―	-89.21%	―	-83.72%	99.56%
AKTX	44 Neutral	$33.51M	―	291.66%	―	―	―
XOMA	43 Neutral	$292.13M	―	-16.20%	―	498.72%	49.92%